Navigation Links
Boston Heart Lab Named 'Most Promising Early Stage Company' 2009 by Silicom Ventures

FRAMINGHAM, Mass., June 29 /PRNewswire/ -- Boston Heart Lab, a pioneer in specialized diagnostics for patients with heart disease, was named "Most Promising Early Stage Company" by Silicom Ventures at the angel investment organization's 2009 Investment Summit, which took place June 2-3, 2009, at Stanford University in California. A four-judge panel selected Boston Heart Lab after evaluating the 20 participating companies for quality of management, vision, execution abilities, and the potential scope of the opportunities. Boston Heart Lab Chief Executive Officer, Wolfgang Daum, Ph.D., accepted the award on behalf of the start-up company, which has seen strong revenues since it began clinical operations in August 2008.

"We're very honored to receive this prestigious award, which is a testament both to the important work our Boston Heart Lab team has done to develop and launch our advanced cardiovascular diagnostic and lipid-testing program, and to the relevance of the services we provide to the marketplace," said Dr. Daum. "While there are other providers of esoteric testing for cardiology, we employ the most-advanced technology available with our proprietary two-dimensional gel electrophoresis of HDL particles and plasma sterol analysis. We deliver clinicians a more complete picture of the patient's health status -- our test results and analyses are the critical building blocks for a personalized treatment plan designed to offer patients the best opportunity for improved health outcomes. This includes more than 35 proprietary tests to assess the patient's cardiac health and risk profile, and a treatment algorithm (Boston Heart Navigator) based on the latest peer-reviewed scientific data."

Commenting on the award, Silicom Ventures' Founder and Managing Director, Gadi Behar, said, "The 2009 Investment Summit showcased 20 impressive early-stage companies in various fields -- from alternative energy and social networking to life sciences. The four-judge panel was unanimous in choosing Boston Heart Lab for its top award in recognition of the start-up's early success in turning the promise of personalized medicine into a reality for cardiac patients. There are 19 million people in the U.S. alone with established heart disease (patients who have had heart attack or stroke) that could benefit from Boston Heart Lab's services, not to mention the 45 million at-risk for cardiac disease. Boston Heart Lab's work will become increasingly important as our healthcare system focuses more and more on outcomes-based medicine to save health dollars and improve outcomes for patients." The judges for the award were three angel investors with extensive investment experience and a venture capitalist partner from Claremont Creek Ventures.

About Silicom Ventures (

Silicom Ventures is one of the leading angel investment organizations in the United States. It links experienced investors (high-tech executives) and venture capitalists with entrepreneurs from around the globe and helps individual angels pool their efforts to gain access to better ventures and better investment deals. Silicom Ventures is leveraging its large network of investors, venture capitalists, industry executives, and technology experts offering entrepreneurs a highly effective screening and early funding process. Beyond funding, Silicom Ventures connects qualified companies with potential business partners, employers, and employees, and technical, professional, and business advisors.

About Boston Heart Lab (

Boston Heart Lab enables cardiologists and other clinicians to prescribe personalized treatment plans for cardiovascular disease and lipid disorders that offer patients the best opportunity for improved health outcomes, based on a panel of tests that provides the most comprehensive assessment available detailing the cause and state of the patient's disease. The company's proprietary two-dimensional gel electrophoresis of HDL particles reveals the entire reverse cholesterol metabolism (HDL) to sub classify the disease; while its proprietary plant sterol analysis evaluates how well the patient produces and absorbs cholesterol. Boston Heart Lab currently offers more than 35 proprietary, state-of-the-art tests to assess the patient's cardiac health and risk profile, and a treatment algorithm for developing a tailored treatment protocol (Boston Heart Navigator) based on the latest peer-reviewed scientific data. A privately held company, Boston Heart Lab began clinical operations after receiving its CLIA license in July 2008.

Media Contact: Caroline Grossman - 781.771.5579 -

Company Contact: Wolfgang Daum - 978-273-8266 -

SOURCE Boston Heart Lab
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Cardinal OMalley Withdraws Caritas Christi From Potential Abortion Scandal
2. Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO
3. Childrens Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center
4. American Life League: Revelations in Boston Archdiocese Caritas Scandal
5. Greater Boston unites to transform health care
6. Boston Scientifics Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting
7. Fifth Annual Games for Health Conference Kicks Off in Boston
8. Clock Ticking In Boston Archdiocese Abortion Scandal
9. Boston Medical Center Selects Bank of America to Assist with Payments Transformation
10. NYP/Weill Cornell physician-scientists present at 2009 American Transplant Congress in Boston
11. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
Post Your Comments:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology: